Call us today 212-583-0100

ENZO Biochem Announces Supply And License Agreement With GlaxoSmithKline

New York, NY, July 20, 2004 -- Enzo Biochem (NYSE:ENZ) announced that its wholly owned subsidiary, Enzo Life Sciences, has signed a supply agreement and license with GlaxoSmithKline (GSK) for Enzo’s proprietary RNA/DNA labeling, detection and amplification technology and products. Financial terms were not disclosed.
 
The agreement includes a non-exclusive license to GlaxoSmithKline under certain of Enzo’s patents to generate genomic information for supporting GSK’s research and development activities. 
 
“We are pleased to enter into this agreement with GSK, one of the world’s leading research-based pharmaceutical and healthcare companies,” said Jim Chinitz, Vice President of Business Development at Enzo Life Sciences.  “In the field of drug target discovery, Enzo’s proprietary technology and products are used to meet the stringent requirements for high quality, reproducible and standardized microarray data”.
 
 In recent years, the analytical power of microarray technology to analyze thousands of genes or genetic variations in parallel, has made this technology a valuable tool for gene expression monitoring and DNA analysis most commonly used in drug discovery research and development, and the study of human disease. The genetic material to be analyzed is often available in minute quantities and therefore must be amplified so that the results can be visualized and quantified.   Enzo Life Sciences has built its proprietary line of products to include complete systems for amplification, labeling and detection.   Enzo’s patented labeling, detection and amplification technology is a critical component for studying gene expression and for performing nucleic acid analysis on microarrays.
 
About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with over 200 patents worldwide, are sold to the life sciences market throughout the world. The Company’s therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn’s Disease. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
 
Contact:
     For: Enzo Biochem, Inc.
     Steve Anreder, 212-532-3232 or Ed Lewis, CEOcast, Inc., 212-732-4300